

Examination Result Report

Sample bar code: 1401659829

Hospital: Renji Hospital, Shanghai Jiao Tong University School of Medicine

Department:

Specimen type: Venous serum

Patient name: Cayun CHEN

Sex:

Age:

Specimen condition:

Inpatient/Outpatient No.:

Submitting physician:

Ward/ward area:

Sampling time:

Tel.:

Bed No.:

Receiving time: 26 August 2025 10:19:35

Clinical Diagnosis:

Examination Item	Results	Indication	Unit	Reference Value	Examination Method
1 Measurement of Infliximab Blood Concentration	3.9		μ g/ml	See result indications 1, 2, 3, 4	Immunoassay
2 Measurement of Serum Concentration of Anti-Infliximab Antibodies	<4		ng/ml	See result indication 5	Immunoassay

※ This examination result is only responsible for the specimens tested. In case of any questions, please propose within seven days!

Examined by: Yaqian YIN

Reviewed by:

Examined at: 26 August 2025 13:27:08

Reported at: 26 August 2025 16:16:51

Address: 4/F, Building 3, No. 51, Jinsigang Road, Guoxiang, Wuzhong District, Suzhou

Tel.: 0512-80821756

Special Seal for Report of Suzhou HeRuiIBD Medical Laboratory (sealed)

Result Indications

- When treating inflammatory bowel disease (IBD), according to the Chinese Experts Consensus on Therapeutic Drug Monitoring of Inflammatory Bowel Disease, the effective trough concentration of infliximab is 3-7 μg/mL, and a higher concentration within this effective range is associated with better clinical outcomes [1].
- When treating ankylosing spondylitis (AS), responders have higher infliximab blood concentrations compared to non-responders (8.2 μg/mL vs. 6.3 μg/mL) [2].
- When treating rheumatoid arthritis (RA), a median serum infliximab trough concentration greater than 1 μg/mL is significantly associated with improvements in the ACR20 response rate, serum C-reactive protein (CRP) levels, the number of tender joints, and the number of swollen joints [3][4].
- When treating psoriasis (Ps), the median range of serum infliximab trough concentrations is 1-4 μg/mL [5]. A concentration greater than 1 μg/mL is significantly associated with an improvement in the Psoriasis Area and Severity Index 75 (PASI75) response [6].
- An anti-infliximab antibody concentration of 20-30 ng/mL represents the cutoff value for distinguishing between positive and negative results and may not necessarily affect the efficacy of infliximab [7]. When the anti-infliximab antibody concentration exceeds 70 ng/mL, it may be associated with infliximab resistance [8].

References:

- Chinese Experts Consensus on Therapeutic Drug Monitoring of Inflammatory Bowel Disease [J]. Chinese Journal of Inflammatory Bowel Diseases, 2018 (04): 253-254-255-256-257-258-259.
- Papamichael K, et al. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019 Aug; 15(8): 837-848.
- Mahboob U Rahman, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis, Ann Rheum Dis 2007;66:1233-1238.
- E. William St. Clair, et al. The Relationship Of serum Infliximab Concentrations to Clinical improvement in Rheumatoid Arthritis, Arthritis Rheum.2002 Jun; 46(6): 1451-9.
- Kristian Reich, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet 2005; 366:1367-74.
- Jennifer S Gall, et al. Infliximab for the treatment of plaque psoriasis. Biologics: Targets & Therapy 2008;2(1) 115-124.
- Bauman LE, et al. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease, Inflamm Bowel Dis.2019 pii: izz143.
- Doucoure El, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic disease, Arthritis Res Ther. 2011 Jun 27;13(3): R105.



Certified Translation (from Chinese into English, source document: electronic copy)

I, Yuanjie Gu, NAATI Certified Translator between Chinese and English (both directions), certify that this is a true and accurate translation of the text provided on the original document.

NAATI Practitioner ID: CPN0ZO95Z

E-mail: justina_guyuanjie@126.com

检验结果报告单


1401659829

医院: 上海交通大学医学院附属仁济医院

科 室:

样品条形码: 标本类型: 静脉血清

病人姓名: 陈采鋆

性 别:

年 龄:

标本情况:

住院号/门诊号:

送检医生:

病 房/区:

采样时间:

联系电话:

床 号:

接收时间: 2025-08-26 10:19:35

临床诊断:

检查项目	结果	提示	单位	参考值	检测方法
1 英夫利西单抗血药浓度测定	3.9		μg/ml	见结果提示1, 2, 3, 4	免疫层析
2 抗英夫利西单抗抗体血清浓度测定	<4		ng/ml	见结果提示5	免疫层析

※本检验结果仅对所检验的标本负责, 如有疑问请在七天内提出!

检验人: 孟雅倩

审核人: 孟雅倩

检验日期: 2025-08-26 13:27:08

报告时间: 2025-08-26 16:16:51

地址: 苏州市吴中区郭巷金丝港路51号3号楼4楼

电话: 0512-80821756



结果提示

- 治疗炎症性肠病(IBD)时, 中国炎症性肠病治疗药物监测专家共识意见: 英夫利西有效谷浓度为3-7ug/mL, 在有效谷浓度范围内, 浓度越高临床结局越好【1】。
- 治疗强直性脊柱炎(AS)时, 有应答者相比失应答者有更高的英夫利西血药浓度 (8.2ug/mL vs 6.3ug/mL) 【2】。
- 治疗类风湿性关节炎(RA)时, 血清中位英夫利西谷浓度大于1ug/mL与ACR20指数、血清CRP、触痛关节数和肿胀关节数等改善显著相关【3】、【4】。
- 治疗银屑病 (Ps) 时, 血清中位英夫利西谷浓度中位数范围1-4ug/mL 【5】。大于1ug/mL与PASI75改善显著相关【6】。
- 抗英夫利西抗体浓度20-30ng/mL是区分阴阳性的临界值, 并不一定影响英夫利西药效【7】。当抗英夫利西抗体浓度 > 70ng/mL 时, 可能与英夫利西耐药相关【8】。

参考文献:

- 【1】中国炎症性肠病治疗药物监测专家共识意见[J].中华炎症肠病杂志,2018(04):253-254-255-256-257-258-259.
- 【2】Papamichael K,et al.Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019 Aug;15(8):837-848.
- 【3】Mahboob U Rahman,et al.Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-1238.
- 【4】E.William St. Clair,et al.The Relationship Of Serum Infliximab Concentrations to Clinical Improvement in Rheumatoid Arthritis. Arthritis Rheum. 2002 Jun;46(6):1451-9.
- 【5】Kristian Reich,et al.Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
- 【6】Jennifer S Gall,et al. Infliximab for the treatment of plaque psoriasis. Biologics: Targets & Therapy 2008;2(1) 115-124.
- 【7】Bauman LE,et al.Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Inflamm?Bowel?Dis.2019 pii: izz143.
- 【8】Ducourau E1,et al.Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic disease. Arthritis Res Ther. 2011 Jun 27;13(3):R105.